Please try another search
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Name | Age | Since | Title |
---|---|---|---|
Russell G. Greig | 71 | 2019 | Independent Chairman of the Board |
Jonathan Eitan Solomon | 46 | 2017 | CEO & Director |
Alan Charles Moses | 74 | 2020 | Independent Director |
Gregory Louis Merril | 58 | 2024 | Independent Director |
Edward L. Williams | 67 | 2023 | Independent Director |
Susan Blum | - | 2024 | Director |
Jesse L. Goodman | 73 | 2024 | Independent Director |
Jonathan Leff | 55 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review